Screener
Tarsus Pharmaceuticals, Inc. TARS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s accounts payable?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accounts payable of $40.14M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accounts payable increased by 43.0% year-over-year, from $28.08M to $40.14M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accounts payable has grown at a 48.9% compound annual growth rate (CAGR), from $2.24M to $16.39M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude